Under Japan's insurance-reimbursed obesity program, 104 non-diabetic patients treated with semaglutide 2.4 mg or tirzepatide achieved mean body weight reductions of approximately 16% over 16 months — a clinically meaningful result consistent with landmark trials. However, after mandated drug cessation, 95% of patients regained weight within 2 months, and mean net weight change deteriorated from −14.4% at treatment endpoint to −7.0% just six months later, erasing roughly half the therapeutic benefit in a matter of weeks.
This finding lands at the center of a fundamental tension in obesity pharmacotherapy policy worldwide: GLP-1 receptor agonists produce robust, reproducible weight loss, but obesity behaves as a chronic, relapsing biological condition driven by hormonal and hypothalamic adaptations that persist long after treatment ends. The STEP 1 extension trial already demonstrated dramatic regain following semaglutide withdrawal; this Japanese cohort now replicates that pattern under a real-world regulatory constraint, adding policy-specific evidence to the biological argument.
Equally notable is the pre-treatment phase: the post-bariatric-surgery subgroup gained an average 2.28 kg during the mandatory 6-month lifestyle intervention — the opposite of its intended effect — while the primary obesity cohort held stable. This suggests lifestyle pre-treatment requirements may be actively counterproductive for patients with complex metabolic histories.
Limitations include modest sample size (n=30 at treatment endpoint), single-center Japanese cohort, and absence of a control arm. Still, this prospective real-world design makes a compelling evidence-based case that time-capped GLP-1 policies are structurally misaligned with the chronic disease model of obesity.